A VC advises Korean entrepreneurs to abandon gradual US entry strategies. The effective model is to "parachute" in—relocating solo to a hub like Boston and immersing oneself in the network. This radical, face-time-centric approach is deemed essential for building the momentum needed for US investment and partnerships.

Iterion CEO Rahul Aras argues that being outside a major biotech hub is a real fundraising hurdle. The issue isn't overt investor bias, but rather the loss of natural networking opportunities—like bumping into investors at a local coffee shop—that are common in dense ecosystems and must be overcome with proactive outreach.

A key debate surrounds the Korean biotech ecosystem: are companies building with a global mindset from day one? Some US investors argue that Korean firms focus too much on their domestic market initially, requiring significant "handholding" to succeed globally, a view contested by local leaders.

Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.

Founded in Minnesota, Cellcuity taps the University of Minnesota and the region's medical device industry for scientific talent. For specialized roles like clinical development, it embraces a distributed team, demonstrating a viable model for building a biopharma company outside of traditional hubs.

Michal Preminger reflects that her former company, located outside a major biotech hub, had to invent solutions in isolation. It lacked the mentorship and deep market and business wisdom that permeates ecosystems like Boston, which would have accelerated its progress.

Dispatch Bio's co-founder argues that while Philadelphia lacks a dense VC scene, this is not a barrier. Capital is highly portable, as shown by their West Coast investors. The real challenge is persuading local Philadelphia capital (PE, hedge funds) to shift from late-stage to riskier, early-stage biotech investments.

Boston's historical strength lies in its co-located universities, capital, and talent. To maintain dominance, its new competitive advantage must be the interconnectivity of these components. The ecosystem that builds the fastest learning and iteration cycles will win, not just the one with the best raw ingredients.

A common clinical need doesn't mean a one-size-fits-all commercial strategy. To scale globally, companies must appreciate the technical, clinical, and commercial differences in each healthcare system and invest in local resources to navigate them successfully.